参考文献/References:
[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] Pavan A,Attili I,Pasello G,et al.Immunotherapy in small-cell lung cancer:from molecular promises to clinical challenges[J].J Immunother Cancer,2019,7(1):205.
[3] Asai N,Ohkuni Y,Kaneko N,et al.Relapsed small cell lung cancer:Treatment options and latest developments[J].Ther Adv Med Oncol,2014,6(2):69-82.
[4] Al Zreibi C,Gibault L,Fabre E,et al.Chirurgie du cancer pulmonaire à petites cellules [Surgery for small-cell lung cancer][J].Rev Mal Respir,2021,38(8):840-847.
[5] Horita N,Yamamoto M,Sato T,et al.Topotecan for relapsed small-cell lung cancer:Systematic review and meta-analysis of 1347 patients[J].Sci Rep,2015,5:15437.
[6] Goto K,Ohe Y,Shibata T,et al.Combined chemotherapy with cisplatin,etoposide,and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer(JCOG0605):A multicentre,open-label,randomised phase 3 trial[J].Lancet Oncol,2016,17(8):1147-1157.
[7] Baena J,Modrego A,Zeaiter A,et al.Lurbinectedin in the treatment of relapsed small cell lung cancer[J].Future Oncol,2021,17(18):2279-2289.
[8] Trigo J,Subbiah V,Besse B,et al.Lurbinectedin as second-line treatment for patients with small-cell lung cancer:A single-arm,open-label,phase 2 basket trial[J].Lancet Oncol,2020,21(5):645-654.
[9] Farago AF,Drapkin BJ,De Ramos LVJA,et al.ATLANTIS:A phase Ⅲ study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line[J].Future Oncol,2019,15(3):231-239.
[10] 张 爽,柳菁菁,杨长良,等.PARP抑制剂在小细胞肺癌的研究进展[J].中国肺癌杂志,2020,23(9):806-810.
[11] Byers LA,Wang J,Nilsson MB,et al.Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1[J].Cancer Discov,2012,2(9):798-811.
[12] Owonikoko TK,Dahlberg SE,Sica GL,et al.Randomized phase Ⅱ trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer:ECOG-ACRIN 2511 study[J].J Clin Oncol,2019,37(3):222-229.
[13] Pietanza MC,Waqar SN,Krug LM,et al.Randomized,double-blind,phase Ⅱ study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer[J].J Clin Oncol,2018,36(23):2386-2394.
[14] Mu Y,Lou J,Srivastava M,et al.SLFN11 inhibits checkpoint maintenance and homologous recombination repair[J].EMBO Rep,2016,17(1):94-109.
[15] Viallard C,Larrivée B.Tumor angiogenesis and vascular normalization:Alternative therapeutic targets[J].Angiogenesis,2017,20(4):409-426.
[16] Lugano R,Ramachandran M,Dimberg A.Tumor angiogenesis:Causes,consequences,challenges and opportunities[J].Cell Mol Life Sci,2020,77(9):1745-1770.
[17] Shen G,Zheng F,Ren D,et al.Anlotinib:A novel multi-targeting tyrosine kinase inhibitor in clinical development[J].J Hematol Oncol,2018,11(1):120.
[18] Cheng Y,Wang Q,Li K,et al.Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer:A randomised,double-blind,placebo-controlled phase 2 study[J].Br J Cancer,2021,125(3):366-371.
[19] Horn L,Reck M,Spigel DR.The Future of immunotherapy in the treatment of small cell lung cancer[J].Oncologist,2016,21(8):910-921.
[20] Rizvi NA,Hellmann MD,Snyder A,et al.Cancer immunology.Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J].Science,2015,348(6230):124-128.
[21] Reck M,Luft A,Szczesna A,et al.Phase Ⅲ randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer[J].J Clin Oncol,2016,34(31):3740-3748.
[22] 张军艳,谷 俊.程序性死亡配体1在肺癌组织中的表达及其与患者病理特征和疾病预后相关性研究[J].陕西医学杂志,2022,51(7):894-897.
[23] Horn L,Mansfield AS,Szczesna A,et al.First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J].N Engl J Med,2018,379(23):2220-2229.
[24] Stewart R,Morrow M,Hammond SA,et al.Identification and characterization of MEDI4736,an antagonistic anti-PD-L1 monoclonal antibody[J].Cancer Immunol Res,2015,3(9):1052-1062.
[25] Paz-Ares L,Dvorkin M,Chen Y,et al.Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN):A randomised,controlled,open-label,phase 3 trial[J].Lancet,2019,394(10212):1929-1939.
[26] Rudin CM,Awad MM,Navarro A,et al.Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer:Randomized,double-blind,phase Ⅲ keynote-604 study[J].J Clin Oncol,2020,38(21):2369-2379.
[27] Owonikoko TK,Park K,Govindan R,et al.Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer:Checkmate 451[J].J Clin Oncol,2021,39(12):1349-1359.
[28] Luo H,Zhang L,Yang B,et al.A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer[J].Invest New Drugs,2020,38(1):148-159.
[29] 荆冠军,赵一鉴.阿帕替尼治疗晚期肺癌对患者血清肿瘤标志物的影响研究[J].陕西医学杂志,2020,49(10):1351-1355.
[30] Fan Y,Zhao J,Wang Q,et al.Camrelizumab plus apatinib in extensive-stage SCLC(PASSION):A multicenter,two-stage,phase 2 trial[J].J Thorac Oncol,2021,16(2):299-309.
[31] Rojo F,Corassa M,Mavroudis D,et al.International real-world study of DLL3 expression in patients with small cell lung cancer[J].Lung Cancer,2020,147:237-243.
[32] Liu SV,Reck M,Mansfield AS,et al.Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab,carboplatin,and etoposide(IMpower133)[J].J Clin Oncol,2021,39(6):619-630.
[33] Rudin CM,Poirier JT,Byers LA,et al.Molecular subtypes of small cell lung cancer:A synthesis of human and mouse model data[J].Nat Rev Cancer,2019,19(5):289-297.
[34] Megyesfalvi Z,Barany N,Lantos A,et al.Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer:An international multicenter study[J].J Pathol,2022,257(5):674-686.
相似文献/References:
[1]彭 峰,彭奕华,张宏华,等.非小细胞肺癌化疗前后血清糖类抗原125、肿瘤异常蛋白水平变化及其与疗效的关系[J].陕西医学杂志,2020,49(7):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
PENG Feng,PENG Yihua,ZHANG Honghua,et al.Changes of serum CA125 and TAP levels before and after chemotherapy for non-small cell lung cancer and their relationship with curative effect[J].,2020,49(10):851.[doi:DOI:10.3969/j.issn.10007377.2020.07.023]
[2]杨 昕,刘 芳,杜 静,等.肺癌癌组织中过氧化物酶增殖体激活受体γ基因表达水平对培美曲塞化疗疗效的预测价值*[J].陕西医学杂志,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
YANG Xin,LIU Fang,DU Jing,et al.Predictive value of PPARγ gene expression level in lung cancer tissue for curative effect of pemetrexed chemotherapy[J].,2020,49(10):1359.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.042]
[3]邵渊.上颌窦癌临床特征及治疗[J].陕西医学杂志,2021,50(4):387.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.001]
[4]雷 普,卢红梅,卜小斌,等.新型内分泌联合化疗治疗高危前列腺癌临床研究[J].陕西医学杂志,2021,50(4):454.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.018]
[5]常瑞霞,可春梅.血小板相关参数和凝血指标在肺癌治疗中的变化及意义[J].陕西医学杂志,2021,50(5):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
CHANG Ruixia,KE Chunmei.Changes and significance of platelet-related parameters and coagulation indexes in treatment of lung cancer[J].,2021,50(10):610.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.024]
[6]孙慧宇,李梅君.替加环素治疗成人急性白血病化疗后中性粒细胞缺乏伴发热疗效及对患者凝血功能、炎症因子的影响[J].陕西医学杂志,2021,50(11):1437.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.029]
SUN Huiyu,LI Meijun.Curative effect of tigecycline in treatment of neutrophil deficiency with fever after chemotherapy in adult acute leukemia and its effect on coagulation function and inflammatory factors in patients[J].,2021,50(10):1437.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.029]
[7]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(10):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
[8]李小龙,陆婉玲,刘秋芳,等.PET/CT引导的不同剂量分割模式治疗老年晚期非小细胞肺癌疗效观察[J].陕西医学杂志,2022,51(10):1270.[doi:DOI:10.3969/j.issn.1000-7377.2022.10.023]
[9]赵 鹏,刘 冬,兰 飞,等.非小细胞肺癌化疗前后血清糖类抗原125、基质金属蛋白酶-9、可溶性程序性死亡配体1水平变化及其与疗效关系研究[J].陕西医学杂志,2022,51(12):1564.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.023]
ZHAO Peng,LIU Dong,LAN Fei,et al.Changes of serum CA125,MMP-9 and sPD-L1 levels before and after chemotherapy in non-small cell lung cancer and their relationship with therapeutic effect[J].,2022,51(10):1564.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.023]
[10]郭家毓,呼 群.小细胞肺癌免疫治疗研究进展[J].陕西医学杂志,2023,52(1):118.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.028]